Monopar Therapeutics Inc. Common Stock
Symbol: MNPR (NASDAQ)
76.65
▼ (-1.03%) -0.795
Company Description:
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Key Stats
- Today's Open: $78.64
- Today's High: $78.455
- Today's Low: $75.025
- Today's Volume: 86.14K
- Yesterday Close: $77.44
- Yesterday High: $79.8
- Yesterday Low: $68.16
- Yesterday Volume: 67.15K
- Last Min Volume: 2
- Last Min High: $76.645
- Last Min Low: $76.645
- Last Min VWAP: $76.645
Company Profile
- Name: Monopar Therapeutics Inc. Common Stock
- Website: https://www.monopartx.com
- Listed Date: 2019-12-19
- Location: WILMETTE, IL
- Market Status: Active
- CIK Number: 0001645469
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $477.80M
- Round Lot: 100
- Outstanding Shares: 6.17M
- Asset Type: CS
RECENT FILINGS FOR MNPR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-26 | 4 | View |
| 2025-09-24 | SCHEDULE 13D/A | View |
| 2025-09-24 | 8-K | View |
| 2025-09-24 | 424B5 | View |
| 2025-09-15 | 8-K | View |
| 2025-09-09 | EFFECT | View |
| 2025-08-29 | S-3 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-07-25 | UPLOAD | View |
| 2025-07-22 | CORRESP | View |
| 2025-07-16 | 4 | View |
| 2025-07-16 | 4 | View |
| 2025-07-16 | 4 | View |
| 2025-07-16 | UPLOAD | View |
| 2025-07-14 | 144 | View |
| 2025-07-14 | 144 | View |
| 2025-07-14 | 144 | View |
| 2025-07-02 | 4 | View |
Latest News on MNPR